secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004227
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus reports preliminary 2022 product revenue of $162M, up 24% YoY, and guides 2023 revenue $165-170M
--------------------------------------------------------------------------------

- Preliminary Q4 2022 product revenue $44.0M, up 10% from Q4 2021.
- Full-year 2022 product revenue $162.0M, at top end of guidance, up 24% year-over-year.
- 2023 product revenue guidance range of $165-170M, citing macroeconomic uncertainty and FX headwinds.
- CEO Obi Greenman notes consistent commercial execution and growing demand for INTERCEPT Blood System in U.S.
- Company expects 2023 to be a bridge year with uncertainty most acute in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312523004227/0001193125-23-004227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312523004227/d426660d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer